VRAX News and Press, Virax Biolabs Group Limited

2026-03-31 10:48:03 ET Denver, Colorado – The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening d...

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation PR Newswire LONDON , March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK...

2026-01-09 13:05:17 ET from H.C. Wainwright issued a price target of $1.00 for VRAX on 2026-01-09 17:20:06. The adjusted price target was set to $1.00. At the time of the announcement, VRAX was trading at $0.3762. VRAX currently trades -88.24% versus its 52 week high of ...

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement PR Newswire Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and sub...

A look at the top 10 most actives in the United States Paranovus Entertainment Technology Ltd. (PAVS) fell 38.3% to $0.034 on volume of 394,331,331 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.2% to $3.02 on volume of 321,190,050 shares Virax Biolabs Group Limited (VRAX)...

A look at the top 10 most actives in the United States Paranovus Entertainment Technology Ltd. (PAVS) fell 39.9% to $0.0331 on volume of 320,255,883 shares Virax Biolabs Group Limited (VRAX) rose 62.9% to $0.6401 on volume of 284,826,214 shares Direxion Daily Semiconductor Bear 3X Shares (S...

Virax Biolabs Group Limited Announces $5 Million Private Placement PR Newswire LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology rese...

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders PR Newswire Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company f...

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes PR Newswire LONDON , Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("V...

Seelos Therapeutics Inc. (SEELQ) is expected to report for quarter end 2025-06-30 Telesis Bio Inc. (TBIO) is expected to report for quarter end 2025-06-30 VG Life Sciences Inc (VGLS) is expected to report for Q2 2025 NexImmune Inc. (NEXI) is expected to report for quarter end 2025-06-...